Literature DB >> 29313195

Bone safety of dual-release hydrocortisone in patients with hypopituitarism.

Stefano Frara1, Sabrina Chiloiro2, Teresa Porcelli3, Antonella Giampietro2, Gherardo Mazziotti4, Laura De Marinis2, Andrea Giustina5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29313195     DOI： 10.1007/s12020-017-1512-1

Source DB:  PubMed          Journal:  Endocrine        ISSN： 1355-008X            Impact factor:   3.633


× No keyword cloud information.
  22 in total

1.  Growth hormone replacement therapy and fracture risk.

Authors:  Andrea Giustina; Gherardo Mazziotti
Journal:  Lancet Diabetes Endocrinol       Date:  2015-04-12       Impact factor: 32.069

Review 2.  Adrenal insufficiency: review of clinical outcomes with current glucocorticoid replacement therapy.

Authors:  Gudmundur Johannsson; Alberto Falorni; Stanko Skrtic; Hans Lennernäs; Marcus Quinkler; John P Monson; Paul M Stewart
Journal:  Clin Endocrinol (Oxf)       Date:  2014-10-10       Impact factor: 3.478

Review 3.  Secondary adrenal insufficiency: from the physiopathology to the possible role of modified-release hydrocortisone treatment.

Authors:  Rosa M Paragliola; Salvatore M Corsello
Journal:  Minerva Endocrinol       Date:  2017-07-27       Impact factor: 2.184

4.  Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation.

Authors:  G Johannsson; A G Nilsson; R Bergthorsdottir; P Burman; P Dahlqvist; B Ekman; B E Engström; T Olsson; O Ragnarsson; M Ryberg; J Wahlberg; B M K Biller; J P Monson; P M Stewart; H Lennernäs; S Skrtic
Journal:  J Clin Endocrinol Metab       Date:  2011-11-23       Impact factor: 5.958

5.  Change in bone mineral density at one year following glucocorticoid withdrawal in kidney transplant recipients.

Authors:  Steven W Ing; Loraine T Sinnott; Sirisha Donepudi; Elizabeth A Davies; Ronald P Pelletier; Nancy E Lane
Journal:  Clin Transplant       Date:  2010-10-21       Impact factor: 2.863

6.  Vertebral fractures assessed with dual-energy X-ray absorptiometry in patients with Addison's disease on glucocorticoid and mineralocorticoid replacement therapy.

Authors:  Valentina Camozzi; Corrado Betterle; Anna Chiara Frigo; Veronica Zaccariotto; Martina Zaninotto; Erica De Caneva; Paola Lucato; Walter Gomiero; Silvia Garelli; Chiara Sabbadin; Monica Salvà; Miriam Dalla Costa; Marco Boscaro; Giovanni Luisetto
Journal:  Endocrine       Date:  2017-08-09       Impact factor: 3.633

7.  Modified-release hydrocortisone decreases BMI and HbA1c in patients with primary and secondary adrenal insufficiency.

Authors:  Marcus Quinkler; Roy Miodini Nilsen; Kathrin Zopf; Manfred Ventz; Marianne Øksnes
Journal:  Eur J Endocrinol       Date:  2015-02-05       Impact factor: 6.664

Review 8.  Glucocorticoid-induced osteoporosis: pathophysiology and therapy.

Authors:  E Canalis; G Mazziotti; A Giustina; J P Bilezikian
Journal:  Osteoporos Int       Date:  2007-06-14       Impact factor: 4.507

Review 9.  Growth hormone, insulin-like growth factors, and the skeleton.

Authors:  Andrea Giustina; Gherardo Mazziotti; Ernesto Canalis
Journal:  Endocr Rev       Date:  2008-04-24       Impact factor: 19.871

Review 10.  Executive summary of the 2013 International Society for Clinical Densitometry Position Development Conference on bone densitometry.

Authors:  John T Schousboe; John A Shepherd; John P Bilezikian; Sanford Baim
Journal:  J Clin Densitom       Date:  2013 Oct-Dec       Impact factor: 2.617
View more
  9 in total

1.  Multiple benefits from dual release hydrocortisone: a "hard" view from bones.

Authors:  D A Vassiliadi; S Tsagarakis
Journal:  Endocrine       Date:  2018-05-17       Impact factor: 3.633

2.  Fabula (non) acta est….Endocrine.

Authors:  Andrea Giustina
Journal:  Endocrine       Date:  2018-12       Impact factor: 3.633

3.  Towards the tailoring of glucocorticoid replacement in adrenal insufficiency: the Italian Society of Endocrinology Expert Opinion.

Authors:  A M Isidori; G Arnaldi; M Boscaro; A Falorni; C Giordano; R Giordano; R Pivonello; C Pozza; E Sbardella; C Simeoli; C Scaroni; A Lenzi
Journal:  J Endocrinol Invest       Date:  2019-11-26       Impact factor: 4.256

4.  Preliminary results from whole-genome expression analysis in patients with secondary adrenal insufficiency treated with modified-release hydrocortisone.

Authors:  Tania Pilli; Sandro Cardinale; Silvia Cantara; Gilda Dalmazio; Raffaella Forleo; Marco Capezzone; Cristian Bassi; Massimo Negrini; Manuela Ferracin; Maria Grazia Castagna
Journal:  Endocrine       Date:  2021-01-08       Impact factor: 3.633

Review 5.  Dual-release hydrocortisone for treatment of adrenal insufficiency: a systematic review.

Authors:  Laura Maria Mongioì; Rosita Angela Condorelli; Federica Barbagallo; Sandro La Vignera; Aldo Eugenio Calogero
Journal:  Endocrine       Date:  2020-01-11       Impact factor: 3.633

6.  Benefits of dual-release hydrocortisone treatment on central adiposity and health-related quality of life in secondary adrenal insufficiency.

Authors:  M Maccario; R Giordano; V Gasco; J Giannelli; L Campioni; E Arvat; E Ghigo; S Grottoli
Journal:  J Endocrinol Invest       Date:  2022-10-17       Impact factor: 5.467

7.  COVID-19 and endocrine and metabolic diseases. An updated statement from the European Society of Endocrinology.

Authors:  M Puig-Domingo; M Marazuela; B O Yildiz; A Giustina
Journal:  Endocrine       Date:  2021-05-08       Impact factor: 3.633

8.  Long-term outcomes of conventional and novel steroid replacement therapy on bone health in primary adrenal insufficiency.

Authors:  Valentina Guarnotta; Claudia Di Stefano; Carla Giordano
Journal:  Sci Rep       Date:  2022-08-02       Impact factor: 4.996

9.  Prednisolone is associated with a worse bone mineral density in primary adrenal insufficiency.

Authors:  Kathrin R Frey; Tina Kienitz; Julia Schulz; Manfred Ventz; Kathrin Zopf; Marcus Quinkler
Journal:  Endocr Connect       Date:  2018-05-02       Impact factor: 3.335
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.